FUNDAMENTALS
EdgeFII/DII
LAURUSLABSLaurus Labs
₹2,294.60-0.49%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
LAURUSLABSNSE · EquityPharmaceuticals

Laurus Labs

ISIN
INE947Q01028
Instrument key
NSE_EQ|INE947Q01028
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹2,294.60-11.40 · -0.49%
Day rangecircuit ₹2,065.20 – ₹2,524.00
2,286.80
2,320.00

as of 21/11/2026, 4:55:43 pm

Open
₹2,294.10
Day high
₹2,320.00
Day low
₹2,286.80
Prev. close
₹2,306.00
Volume
8.79 L
VWAP
₹2,303.73

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

1 year · daily candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · 1Y
+134.57%
978.20 → 2,294.60
Period high
₹2,488.00
11/11/2026
Period low
₹917.95
2/2/2026
From high
-7.77%
+149.97% from low
Avg volume
21.42 L
53.13 Cr total
Volatility · ann.
32.4%
248 candles · 136 up / 112 down
20 Nov 2026O 2,294.10H 2,320.00L 2,286.80C 2,294.60Vol 8.79 L
SMA 20SMA 50Averages need 50 candles before they begin
Candle data248 rows of open, high, low, close and volumeShowHide
20 Nov 20262,294.102,320.002,286.802,294.60+0.02%33.208.79 L
19 Nov 20262,322.502,328.902,272.602,306.00-0.71%56.3018.95 L
18 Nov 20262,345.002,362.602,317.002,322.50-0.96%45.6016.13 L
17 Nov 20262,220.002,348.802,214.802,338.00+5.32%134.0048.90 L
16 Nov 20262,430.002,439.002,190.002,220.00-8.64%249.0068.44 L
13 Nov 20262,400.002,446.902,394.002,424.00+1.00%52.9022.78 L
12 Nov 20262,427.002,434.202,380.002,400.00-1.11%54.2017.66 L
11 Nov 20262,480.002,488.002,416.902,429.00-2.06%71.1041.34 L
9 Nov 20262,351.502,480.002,351.502,454.00+4.36%128.5040.26 L
8 Nov 20262,333.902,375.002,333.902,370.00+1.55%41.104.27 L

Historical price and volume data · Showing 1–10 of 248

1 / 25

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

93.07
Company
93.07
Sector
-45.02

Worse than sector by 307%

P/B

Price ÷ book value per share

20.46
Company
20.46
Sector
4.21

Worse than sector by 386%

ROA

Net income ÷ total assets

11.58%
Company
11.58%
Sector
1.19%

Better than sector by 873%

ROE

Net income ÷ shareholders' equity

22.11%
Company
22.11%
Sector
-0.4%

Better than sector by 5627%

ROCE

EBIT ÷ capital employed

20.91%
Company
20.91%
Sector
15.44%

Better than sector by 35%

Quick Ratio

Liquid assets ÷ current liabilities

0.68
Company
0.68
Sector
4.8

Worse than sector by 86%

EV/EBITDA

Enterprise value ÷ EBITDA

52.54
Company
52.54
Sector
22.86

Worse than sector by 130%

04/Business

About the company

Sector: Pharmaceuticals

Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers an integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. It operates through four divisions: Generics API, Generics FDF, CDMO custom synthesis (Laurus Synthesis), and Biotechnology (Laurus Bio). The Generics API is a third-party API supplier for antiretrovirals. The Generic FDF business focuses on oral solid formulations. Laurus Synthesis provides drug development and manufacturing services to global pharma, crop science, animal health, and others. Laurus Bio offers comprehensive services from clone and strain engineering to production, supporting clients across the microbial precision fermentation spectrum. Its solutions cater for sectors, such as regenerative medicine, vaccines, cultured meat, and others.

Sector market cap (INR)
₹1,24,002 Cr

reported in crore

Sector market cap (USD)
$13.78B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Standalone income statement

Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Mar 2026
₹6,167 Cr
+15.97% vs Mar 2025
Net profit · Mar 2026
₹740 Cr
+94.66% vs Mar 2025
Operating margin
16.1%
was 9.5%
Revenue CAGR · 4p
2.1%
profit -0.9% · op -1.9%
Filed order
Revenue6,1675,3174,8605,789
Revenue growthreported16.0%9.4%-16.1%—
Operating profit9945043011,051
Operating profit growthreported97.3%67.1%-71.3%—
Operating marginderived16.1%9.5%6.2%18.2%
Net profit740380224760
Net profit growthreported94.7%70.0%-70.6%—
Net marginderived12.0%7.2%4.6%13.1%
EPS — basic₹/share, annual13.727.064.1514.14

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue6,0895,2174,8125,773
Other Income771004716
Total Revenue6,1675,3174,8605,789
Total Expenses5,1724,8144,5584,738
Profit Before Tax9945043011,051
Tax25412378291
Profit After Tax740380224760
EPS - Basic13.727.064.1514.14
EPS - Diluted13.707.054.1514.09

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Standalone balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹9,540 Cr
+11.10% YoY
Total liabilities
₹4,288 Cr
Net worth
₹5,252 Cr
Liabilities ÷ assets
44.9%
lower means a lighter balance sheet
Filed order
Total assets9,5408,5877,6676,958
Total liabilities4,2884,0233,4602,901
Net worthderived5,2524,5644,2074,057
Liabilities ÷ assetsderived44.9%46.8%45.1%41.7%
Asset growthderived11.1%12.0%10.2%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets5,1774,5804,1503,787
Current Assets4,3634,0073,5173,171
Total Assets9,5408,5877,6676,958
Current Liabilities3,2583,1622,7362,106
Net Current Asset1,1058457811,065
Non-Current Liabilities1,030861725795
Equity Capital5,2524,5644,2074,057
Total Equity & Liabilities9,5408,5877,6676,958

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Standalone cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹1,385 Cr
+156.44% YoY
Investing
-₹847 Cr
Financing
-₹551 Cr
Free cash flow
₹538 Cr
operating + investing
Filed order
Operating activities1,385540659882
Operating changereported156.4%-18.0%-25.3%—
Investing activities-847-592-757-735
Investing changereported-43.2%21.8%-2.9%—
Financing activities-55159139-185
Financing changereported-1028.4%-57.5%175.3%—
Net cash flowderived-13841-39
Free cash flowoperating + investing538-52-98146

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax9945043011,051
Income before WC changes1,5441,0027801,494
Change in Assets-400-527-310-87
Change in Liabilities526199287-257
Change in WC126-328-23-344
Cash flow from Operations1,385540659882
Cash flow from Investing-847-592-757-735
Cash flow from Financing-55159139-185
Total Cash Flow-13841-39
Cash (Start of the year)5043140
Cash (End of the year)3850431

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
27.47%
0.00 pts QoQ
FII
30.84%
+2.84 pts QoQ
DII (other)
3.60%
+0.01 pts QoQ
Mutual funds
8.26%
-1.89 pts QoQ
Retail & others
29.83%
-0.95 pts QoQ
Filed order
Promoters27.5%27.5%27.5%27.5%
FII30.8%28.0%25.8%26.5%
DII (other)3.6%3.6%2.7%2.9%
Mutual funds8.3%10.2%11.2%9.5%
Retail & others29.8%30.8%32.7%33.6%
Promoters — QoQ changepts, derived0.0%-0.0%0.0%—
FII — QoQ changepts, derived2.8%2.2%-0.7%—
DII (other) — QoQ changepts, derived0.0%0.8%-0.2%—
Mutual funds — QoQ changepts, derived-1.9%-1.1%1.7%—
Retail & others — QoQ changepts, derived-1.0%-1.9%-0.9%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendInterim₹1.0050.0%06 Nov 202606 Nov 202629 Oct 2026
DividendInterim₹1.2060.0%08 May 202608 May 202630 Apr 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

5102050
  • Thumbnail: Beyond the big names: 6 NIFTY 500 stocks that quietly rallied up to 200% in six months
    3d ago18/11/2026, 3:51:22 pm
    Beyond the big names: 6 NIFTY 500 stocks that quietly rallied up to 200% in six months

    Cupid, Ather Energy, and Laurus Labs are among the top six stocks which have quietly rallied up to the tune of 200% in the last six months despite market volatility. Here's what investors need to know.

Showing 1–1 of 1 article